NeuroPace Inc (NAS:NPCE)
$ 7.53 -0.07 (-0.92%) Market Cap: 216.62 Mil Enterprise Value: 232.78 Mil PE Ratio: 0 PB Ratio: 15.23 GF Score: 55/100

Neuropace Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 05:00PM GMT
Release Date Price: $2.65 (+12.77%)
Lilia;Celine Breton Lozada
JPMorgan Chase & Co, Research Division - Research Analyst

Good morning, everyone. I'm Lily Lozada. I'm on the medtech team here at JPMorgan, and I'm happy to have the NeuroPace management team with us here today. I'll pass things off to CEO, Mike Favet, before we open things up for Q&A.

Michael L. Favet
NeuroPace, Inc. - President, CEO & Director

Thank you. Good morning, everyone. I am here today to tell you about what's happening in NeuroPace. So starting with a little bit of an overview for people that are not as familiar with the story. At NeuroPace, our mission is to transform the lives of people living with epilepsy. The condition itself, epilepsy is a condition that affects about 3.4 million people in the United States, has a tremendous cost to the health care system, impact to patients, impact to family members and caregivers of patients. And many of those patients are looking for treatment options when medical management does not work for them. And that's the place that NeuroPace comes in.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot